Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype.[1][2] It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models,[3] and progressed as far as Phase II clinical trials for Parkinson's disease,[4] where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.
^Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, et al. (March 2000). "Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist". Pharmaceutica Acta Helvetiae. 74 (2–3): 125–30. doi:10.1016/S0031-6865(99)00024-2. PMID10812948.
^Wagner FF, Comins DL (October 2006). "Expedient five-step synthesis of SIB-1508Y from natural nicotine". The Journal of Organic Chemistry. 71 (22): 8673–5. doi:10.1021/jo0616052. PMID17064057.